Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA

Cancer Immunology, Immunotherapy

Volumn 59, Issue 7, 2010, Pages 1131-1135

  Gabitzsch, Elizabeth S ^a   Xu, Younong ^a   Balint Jr , Joseph P ^a   Hartman, Zachary C ^b   Lyerly, H Kim ^b   Jones, Frank R ^a  

^a Etubics Corporation   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

Adenovirus 5 vector; Carcinoembryonic antigen; Immune induction

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; DNA POLYMERASE; CANCER VACCINE; VIRUS PROTEIN;

ADENOCARCINOMA; ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL STRAIN HEK293; CELLULAR IMMUNITY; CONTROLLED STUDY; GENE DELETION; GENE INSERTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOPHARMACOLOGY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADENOVIRUS; ANIMAL; C57BL MOUSE; CELL LINE; EXPERIMENTAL NEOPLASM; GENE VECTOR; GENETICS; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ADENOVIRIDAE; ADENOVIRUS E1 PROTEINS; ADENOVIRUS E2 PROTEINS; ANIMALS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL LINE; CELL LINE, TUMOR; GENE DELETION; GENETIC VECTORS; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; TREATMENT OUTCOME;

EID: 77953052831     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0847-8     Document Type: Article

References (24)

1. CJ Kirk D Hartigan-O'Connor JJ Mule 2001 The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally Cancer Res 61 8794 8802 1:CAS:528:DC%2BD38Xht1OmsA%3D%3D 11751401
2. CJ Kirk D Hartigan-O'Connor BJ Nickoloff JS Chamberlain M Giedlin L Aukerman JJ Mule 2001 T cell-dependant antitumor immunity mediated by secondary lymphoid tissue chemokine; augmentation of dendritic cell-based immunotherapy Cancer Res 61 2062 2070 1:CAS:528:DC%2BD3MXit1OgsLw%3D 11280767
3. JM Polo TW Dubensky 2002 Virus-based vectors for human vaccine applications Drug Discov Today 1 53 100
4. M Liniger A Zuniga HY Naim 2007 Use of viral vectors for the development of vaccines Expert Rev Vaccines 6 255 266 10.1586/14760584.6.2.255 1:CAS:528:DC%2BD2sXjvVKjsbo%3D 17408374 (Pubitemid 46613525)
5. Gaydos CA, Gaydos JC (2004) Adenovirus vaccine. In: Orenstein WA (ed) Vaccines, 4th edn. Sauders, Philadelphia, pp 863-885
6. Z Papp LA Babiuk ME Baca-Estrada 1999 The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1 Vaccine 17 933 943 10.1016/S0264-410X(98)00279-5 1:CAS:528:DyaK1MXhs1Cnsbk%3D 10067700 (Pubitemid 29074748)
7. K McCoy N Tatsis B Korioth-Schmitz MO Lasaro SE Hensley SW Lin Y Li W Giles-Davis A Cun D Zhou Z Xiang NL Letvin HC Ertl 2007 Effect of preexisting immunity to adenovirus human serotype 5 antigens on the Immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors J Virol 81 12 6594 6604 10.1128/JVI.02497-06 1:CAS:528:DC%2BD2sXmt1Ortr8%3D 17428852 (Pubitemid 46878063)
8. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, Wolfe ND, Aste-Mezaga M, Casimiro DR, Coplan P, Straus WL, Shiver JW (2009) International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28:950-957
9. A Amalfitano CR Begy JS Chamberlain 1996 Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors Proc Natl Acad Sci USA 93 3352 3356 10.1073/pnas.93.8.3352 1:CAS:528: DyaK28XisVWisb0%3D 8622940 (Pubitemid 26125623)
10. BL Hodges D Serra H Hu CA Begy JS Chamberlain A Amalfitano 2000 Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein J Gene Med 2 250 259 10.1002/1521-2254(200007/08)2: 4<250::AID-JGM113>3.0.CO;2-3 1:CAS:528:DC%2BD38Xlt1yqtbo%3D 10953916
11. A Amalfitano MA Hauser H Hu D Serra CR Begy JS Chamberlain 1998 Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted J Virol 72 926 933 1:CAS:528:DyaK1cXlt1Cktg%3D%3D 9444984
12. RS Everett BL Hodges EY Ding F Xu D Serra A Amalfitano 2003 Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors Hum Gene Ther 14 1715 1726 10.1089/104303403322611737 1:CAS:528:DC%2BD3sXps12htbg%3D 14670123
13. ES Gabitzsch Y Xu L Yosida JP Balint RB Gayle A Amalfitano FR Jones 2009 A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant based vaccine used to induce cell mediated immune responses Immunol Lett 122 44 51 10.1016/j.imlet.2008.11.003 1:CAS:528:DC%2BD1MXitVyht70%3D 19073216
14. JA Thompson F Grunert W Zimmerman 1991 Carcinoembryonic antigen gene family: molecular biology and clinical perspectives J Clin Lab Anal 5 344 366 10.1002/jcla.1860050510 1:CAS:528:DyaK3MXmslWlsLs%3D 1941355
15. JE Shively JD Beatty 1985 CEA-related antigens: molecular biology and clinical significance Crit Rev Oncol Hematol 2 355 399 10.1016/S1040-8428(85) 80008-1 1:STN:280:DyaL2M7nslajtQ%3D%3D 3886178
16. J Schlom 1986 Basic principle and applications of monoclonal antibodies in the management of carcinomas: the Richard and Hinda Tosenthal Foundation Award Lecture Cancer Res 46 3225 3238 1:STN:280:DyaL283hslOhsw%3D%3D 3518915
17. NL Berinstein 2002 Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review J Clin Oncol 20 2197 2207 10.1200/JCO.2002.08.017 1:CAS:528:DC%2BD38XjvVKms7o%3D 11956282 (Pubitemid 34408812)
18. JL Marshall RJ Hoyer MA Toomey, et al. 2000 Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses J Clin Oncol 18 3964 3973 1:STN:280:DC%2BD3M%2Fnt1GisQ%3D%3D 11099326
19. JL Marshall MJ Hawkins KY Tsang E Richmond JE Pedicano MZ Zhu J Schlom 1999 Phase I study in cancer patients of a replication- defective avipox recombinant vaccine that expresses human carcinoembryonic antigen J Oncol 17 332 337 1:CAS:528:DyaK1MXltVyrtw%3D%3D
20. KY Tsang S Zaremba CA Nieroda MZ Zhu JM Hamilton J Schlom 1995 Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine J Nat Cancer Inst 87 982 990 10.1093/jnci/87.13.982 1:CAS:528:DyaK2MXnsVemu7w%3D 7629885
21. A Samanci Q Yi J Fagerberg K Strigård G Smith U Rudén B Wahren H Mellstedt 1998 Pharmacological administration of granulocyte/ macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen Cancer Immunol Immunother 47 131 142 10.1007/s002620050513 1:CAS:528:DyaK1MXitVWl 9829838 (Pubitemid 28518327)
22. M Mincheff I Altankova S Zoubak S Tchakarov C Botev S Petrov E Krusteva G Kurteva P Kurtev V Dimitrov M Ilieva G Georgiev T Lissitchkov I Chernozemski HT Meryman 2001 In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer-changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile Crit Rev Oncol Hematol 39 1-2 125 132 10.1016/S1040-8428(01) 00111-1 1:STN:280:DC%2BD38%2Fit1aitw%3D%3D 11418309 (Pubitemid 32551993)
23. PF Robbins JA Kantor M Salgaller PH Hand PD Fernsten J Schlom 1991 Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line Caner Res 51 3657 3662 1:CAS:528: DyaK3MXlt12jsbc%3D
24. Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ (1998) Mice transgenic for carcinoembryonic antigen as a model for immunotherapy. Cancer Res 58:1468-1477